From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations
暂无分享,去创建一个
Garry R. Cutting | Harvey B. Pollard | Jeffrey L. Brodsky | William E. Balch | Jeong S. Hong | G. Lukács | H. Pollard | D. Cyr | J. Brodsky | W. Balch | G. Cutting | W. Guggino | R. Frizzell | D. Sheppard | Scott A. Houck | Z. Cai | W. Skach | Jeong-Soo Hong | E. Sorscher | Douglas M. Cyr | William R. Skach | William B. Guggino | Gergely L. Lukacs | Raymond A. Frizzell | Eric J. Sorscher | Gudio Veit | Radu G. Avramescu | Annette N. Chiang | Zhiwei Cai | Kathryn W. Peters | David N. Sheppard | K. Peters | Gudio Veit | R. Avramescu
[1] Hua,et al. Identification of , 2000, Journal of insect physiology.
[2] K. Du,et al. Correction of Both NBD1 Energetics and Domain Interface Is Required to Restore ΔF508 CFTR Folding and Function , 2012, Cell.
[3] J. Riordan,et al. Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[4] G. Lukács,et al. C-terminal Truncations Destabilize the Cystic Fibrosis Transmembrane Conductance Regulator without Impairing Its Biogenesis , 1999, The Journal of Biological Chemistry.
[5] P. Margolis,et al. The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. , 2001, American journal of respiratory and critical care medicine.
[6] R. Boucher. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. , 2007, Annual review of medicine.
[7] Ewart A. C. Thomas,et al. A Little CFTR Goes a Long Way: CFTR-Dependent Sweat Secretion from G551D and R117H-5T Cystic Fibrosis Subjects Taking Ivacaftor , 2014, PloS one.
[8] M. Welsh,et al. Mutations in CFTR associated with mild-disease-form CI- channels with altered pore properties , 1993, Nature.
[9] A stabilizing influence: CAL PDZ inhibition extends the half-life of ΔF508-CFTR. , 2010, Angewandte Chemie.
[10] J. Gustafson,et al. Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.
[11] Nikhil T. Awatade,et al. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis , 2014, EBioMedicine.
[12] S. Hilton,et al. Improvement in clinical markers in CF patients using a reduced glutathione regimen: an uncontrolled, observational study. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[13] S. Peltz,et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. , 2014, The Lancet. Respiratory medicine.
[14] M. Welsh,et al. Loss of Anion Transport without Increased Sodium Absorption Characterizes Newborn Porcine Cystic Fibrosis Airway Epithelia , 2010, Cell.
[15] A. Di Leonardo,et al. Toward a Rationale for the PTC124 (Ataluren) Promoted Readthrough of Premature Stop Codons: A Computational Approach and GFP-Reporter Cell-Based Assay , 2014, Molecular pharmaceutics.
[16] Chris Fellner,et al. CFTR Modulators for the Treatment of Cystic Fibrosis. , 2014, P & T : a peer-reviewed journal for formulary management.
[17] Xiaohong Huang,et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.
[18] D. Cyr. Arrest of CFTRΔF508 folding , 2005, Nature Structural &Molecular Biology.
[19] Kai Du,et al. Cooperative assembly and misfolding of CFTR domains in vivo. , 2009, Molecular biology of the cell.
[20] I. Sabirzhanova,et al. Rescue of NBD2 Mutants N1303K and S1235R of CFTR by Small-Molecule Correctors and Transcomplementation , 2015, PloS one.
[21] M. Welsh,et al. Contribution of Proline Residues in the Membrane-spanning Domains of Cystic Fibrosis Transmembrane Conductance Regulator to Chloride Channel Function* , 1996, The Journal of Biological Chemistry.
[22] F. van Goor,et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[23] R. Tarran,et al. The CF salt controversy: in vivo observations and therapeutic approaches. , 2001, Molecular cell.
[24] Rafał Bartoszewski,et al. ΔF508 CFTR Surface Stability Is Regulated by DAB2 and CHIP-Mediated Ubiquitination in Post-Endocytic Compartments , 2015, PloS one.
[25] Shio‐Jean Lin,et al. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses—changes with age and treatment , 2014, Pediatric pulmonology.
[26] A. Verkman,et al. Hyperviscous airway periciliary and mucous liquid layers in cystic fibrosis measured by confocal fluorescence photobleaching , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[27] J. Marshall,et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis , 1990, Cell.
[28] J C Olsen,et al. Identification of a splice site mutation (2789+5 G>A) associated with small amounts of normal CFTRmRNA and mild cystic fibrosis , 1997, Human mutation.
[29] D. Cyr,et al. Increased folding and channel activity of a rare cystic fibrosis mutant with CFTR modulators. , 2011, American journal of physiology. Lung cellular and molecular physiology.
[30] J. Riordan,et al. Disease-associated Mutations in the Extracytoplasmic Loops of Cystic Fibrosis Transmembrane Conductance Regulator Do Not Impede Biosynthetic Processing but Impair Chloride Channel Stability* , 2001, The Journal of Biological Chemistry.
[31] S. McColley,et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. , 2014, The Lancet. Respiratory medicine.
[32] S Grinstein,et al. The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. , 1993, The Journal of biological chemistry.
[33] J. Clancy,et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. , 2010, The New England journal of medicine.
[34] N. Bradbury,et al. A Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Generates a Novel Internalization Sequence and Enhances Endocytic Rates* , 2003, The Journal of Biological Chemistry.
[35] M. Yasui,et al. Curcumin and genistein additively potentiate G551D-CFTR. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[36] J. Riordan,et al. The cystic fibrosis transmembrane conductance regulator. , 1993, Annual review of physiology.
[37] Marisa Sousa,et al. Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction. , 2013, Chemistry & biology.
[38] B. Kerem,et al. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. , 2007, The Journal of clinical investigation.
[39] L. Tsui,et al. Erratum: Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA , 1989, Science.
[40] Jinglan Zhou,et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.
[41] J. Schacht,et al. Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor. , 2014, American journal of respiratory cell and molecular biology.
[42] Garry R. Cutting,et al. Cystic fibrosis genetics: from molecular understanding to clinical application , 2014, Nature Reviews Genetics.
[43] D. Clarke,et al. Corrector VX-809 stabilizes the first transmembrane domain of CFTR. , 2013, Biochemical pharmacology.
[44] Y. Sohma,et al. G551D and G1349D, Two CF-associated Mutations in the Signature Sequences of CFTR, Exhibit Distinct Gating Defects , 2007, The Journal of general physiology.
[45] G. Lukács,et al. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression , 2014, Science Translational Medicine.
[46] F. Collins,et al. Cystic fibrosis: molecular biology and therapeutic implications. , 1992, Science.
[47] G. Cutting,et al. Update on gene modifiers in cystic fibrosis , 2008, Current opinion in pulmonary medicine.
[48] A. Edelman,et al. Cystic Fibrosis Phenotype Associated with Pancreatic Insufficiency Does Not Always Reflect the cAMP-dependent Chloride Conductive Pathway Defect , 1997, The Journal of Biological Chemistry.
[49] G. Lukács,et al. Mechanism-based corrector combination restores ΔF508-CFTR folding and function , 2013, Nature Chemical Biology.
[50] A. Toye,et al. CFTR potentiators partially restore channel function to A561E‐CFTR, a cystic fibrosis mutant with a similar mechanism of dysfunction as F508del‐CFTR , 2014, British journal of pharmacology.
[51] J. Clancy,et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation , 2011, Thorax.
[52] J C Olsen,et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. , 1994, The New England journal of medicine.
[53] John R Yates,et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. , 2010, Nature chemical biology.
[54] S. Peltz,et al. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model , 2008, Proceedings of the National Academy of Sciences.
[55] S Grinstein,et al. Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. , 1994, The EMBO journal.
[56] Kai Du,et al. The ΔF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR , 2005, Nature Structural &Molecular Biology.
[57] Hong Yu Ren,et al. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1 , 2013, Molecular biology of the cell.
[58] M. Welsh,et al. Reduced Airway Surface pH Impairs Bacterial Killing in the Porcine Cystic Fibrosis Lung , 2012, Nature.
[59] Meenal Patel,et al. PTC124 targets genetic disorders caused by nonsense mutations , 2007, Nature.
[60] F. Vermeulen,et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. , 2010, American journal of respiratory and critical care medicine.
[61] Soo-Jung Kim,et al. Mechanisms of CFTR Folding at the Endoplasmic Reticulum , 2012, Front. Pharmacol..
[62] P. Farrell,et al. The prevalence of cystic fibrosis in the European Union. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[63] A. Hamosh,et al. CFTR nonsense mutations G542X and W1282X associated with severe reduction of CFTR mRNA in nasal epithelial cells. , 1992, Human molecular genetics.
[64] S. McColley,et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. , 2015, The Lancet. Respiratory medicine.
[65] Philip J. Thomas,et al. Requirements for Efficient Correction of ΔF508 CFTR Revealed by Analyses of Evolved Sequences , 2012, Cell.
[66] V. Baranov,et al. Two new mutations detected by single-strand conformation polymorphism analysis in cystic fibrosis from Russia , 1993, Human Genetics.
[67] H. Blau,et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis , 2011, European Respiratory Journal.
[68] R. Castile,et al. Detrimental effects of secondhand smoke exposure on infants with cystic fibrosis , 2015, Pediatric pulmonology.
[69] A. Luini,et al. Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on ΔF508 cystic fibrosis transmembrane conductance regulator , 2012, Autophagy.
[70] Jason C. Young,et al. Peripheral Protein Quality Control Removes Unfolded CFTR from the Plasma Membrane , 2010, Science.
[71] F. van Goor,et al. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[72] George P Patrinos,et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene , 2013, Nature Genetics.
[73] T. Ma,et al. Nanomolar Affinity Small Molecule Correctors of Defective ΔF508-CFTR Chloride Channel Gating* , 2003, Journal of Biological Chemistry.
[74] I. Kerr. Structure and association of ATP-binding cassette transporter nucleotide-binding domains. , 2002, Biochimica et biophysica acta.
[75] N. Pedemonte,et al. Influence of cell background on pharmacological rescue of mutant CFTR. , 2010, American journal of physiology. Cell physiology.
[76] P. Negulescu,et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.
[77] J. Zieleński,et al. Cystic fibrosis: genotypic and phenotypic variations. , 1995, Annual review of genetics.
[78] Matthias Griese,et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.
[79] P. Diggle,et al. Low socioeconomic status is associated with worse lung function in the Danish cystic fibrosis population , 2014, European Respiratory Journal.
[80] A. Yoda,et al. Structure-activity relationships of cardiotonic steroids for the inhibition of sodium- and potassium-dependent adenosine triphosphatase. V. Dissociation rate constants of digitoxin acetates. , 1975, Molecular pharmacology.
[81] D. Meyerholz,et al. Origins of cystic fibrosis lung disease. , 2015, The New England journal of medicine.
[82] M. Welsh,et al. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis , 1993, Cell.
[83] J. Riordan,et al. Functional analysis of the C-terminal boundary of the second nucleotide binding domain of the cystic fibrosis transmembrane conductance regulator and structural implications. , 2002, The Biochemical journal.
[84] J. Elborn,et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.
[85] F. Collins,et al. Molecular basis of defective anion transport in L cells expressing recombinant forms of CFTR. , 1993, Human molecular genetics.
[86] S. Rowe,et al. Improved clinical and radiographic outcomes after treatment with ivacaftor in a young adult with cystic fibrosis with the P67L CFTR mutation. , 2015, Chest.
[87] Pascal Barbry,et al. Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation , 1991, Nature.
[88] J. Britton,et al. Association between socioeconomic status, sex, and age at death from cystic fibrosis in England and Wales (1959 to 2008): cross sectional study , 2011, BMJ : British Medical Journal.
[89] X. Estivill,et al. Cystic fibrosis in a southern Brazilian population: characteristics of 90% of the alleles , 2007, Clinical genetics.
[90] G. Cutting. Modifier genes in Mendelian disorders: the example of cystic fibrosis , 2010, Annals of the New York Academy of Sciences.
[91] M. Welsh,et al. Mechanism of dysfunction of two nucleotide binding domain mutations in cystic fibrosis transmembrane conductance regulator that are associated with pancreatic sufficiency. , 1995, The EMBO journal.
[92] J. Zieleński. Genotype and Phenotype in Cystic Fibrosis , 2000, Respiration.